Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a

• Thomas C. Darton ,

  * E-mail: thomas.darton@paediatrics.ox.ac.uk

  Affiliation Oxford Vaccine Group, Department of Paediatrics, and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  http://orcid.org/0000-0003-2209-9956

  ⨯
• Claire Jones,

  Affiliation Oxford Vaccine Group, Department of Paediatrics, and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  ⨯
• Christoph J. Blohmke,

  Affiliation Oxford Vaccine Group, Department of Paediatrics, and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  ⨯
• Claire S. Waddington,

  Affiliation Oxford Vaccine Group, Department of Paediatrics, and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  ⨯
• Liqing Zhou,

  Affiliation Oxford Vaccine Group, Department of Paediatrics, and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  ⨯
• Anna Peters,

  Affiliation Oxford Vaccine Group, Department of Paediatrics, and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  ⨯
• Kathryn Haworth,

  Affiliation Oxford Vaccine Group, Department of Paediatrics, and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  ⨯
• Rebecca Sie,

  Affiliation Oxford Vaccine Group, Department of Paediatrics, and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  ⨯
• Christopher A. Green,

  Affiliation Oxford Vaccine Group, Department of Paediatrics, and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  ⨯
• Catherine A. Jeppesen,

  Affiliation Oxford Vaccine Group, Department of Paediatrics, and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  ⨯
• Maria Moore,

  Affiliation Oxford Vaccine Group, Department of Paediatrics, and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  ⨯
• Ben A. V. Thompson,

  Affiliation Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom

  ⨯
• Tessa John,

  Affiliation Oxford Vaccine Group, Department of Paediatrics, and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  ⨯
• Robert A. Kingsley,

  Affiliation Microbial Pathogenesis Group, Wellcome Trust Sanger Institute, Hinxton, United Kingdom

  ⨯
• Ly-Mee Yu,

  Affiliation Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom

  ⨯
• Merryn Voysey,

  Affiliation Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom

  ⨯
• Zoe Hindle,

  Affiliation Emergent Product Development UK Ltd, Emergent BioSolutions, Wokingham, United Kingdom

  ⨯
• Stephen Lockhart,

  Affiliation Emergent Product Development UK Ltd, Emergent BioSolutions, Wokingham, United Kingdom

  ⨯
• Marcelo B. Sztein,

  Affiliation Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

  ⨯
• Gordon Dougan,

  Affiliation Microbial Pathogenesis Group, Wellcome Trust Sanger Institute, Hinxton, United Kingdom

  ⨯
• Brian Angus,

  Affiliation Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

  ⨯
• Myron M. Levine,

  Affiliation Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

  ⨯
•  [ ... ],
• Andrew J. Pollard

  Affiliation Oxford Vaccine Group, Department of Paediatrics, and the NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  ⨯
• [ view all ]
• [ view less ]